Chemoablation of metastatic melanoma using intralesional Rose Bengal

Melanoma Research

Volumn 18, Issue 6, 2008, Pages 405-411

  Thompson, John F ^a,b   Hersey, Peter ^a,c   Wachter, Eric ^d  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c NEWCASTLE MATER HOSPITAL   (Australia)

^d Provectus Pharmaceuticals Inc   (United States)

Author keywords

Bystander; Cancer; Locoregional; Melanoma; Metastasis; Rose Bengal

Indexed keywords

PV 10; ROSE BENGAL; UNCLASSIFIED DRUG;

AGED; ARTICLE; BYSTANDER EFFECT; CANCER LOCALIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TARGETING; DRUG TOLERABILITY; FEMALE; HUMAN; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INSOMNIA; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; RECURRENT CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; FEMALE; FLUORESCENT DYES; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MELANOMA; ROSE BENGAL; SKIN NEOPLASMS;

EID: 56849112041     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32831328c7     Document Type: Article

References (27)

1. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005; 365:687-701.
2. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17 600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19:3622-3634.
3. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-3648.
4. Green FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M, editors. AJCC cancer staging manual, 6th ed. New York: Springer-Verlag; 2002. pp. 209-220.
5. Sanki A, Kam PCA,T hompson JF. Long term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology. Ann Surg 2007; 245:591-596.
6. Sondak VK, Sabel MS, Mule JJ. Allogeneic and autologous melanoma vaccines: where have we been and where are we going? Clin Cancer Res 2006; 12:2337s-2341s.
7. Wolchok JD, Livingston PO. Vaccines for melanoma: translating basic immunology into new therapies. Lancet Oncol 2001; 2:205-211.
8. Hersey P. Adjuvant therapy for high-risk primary and resected metastatic melanoma. Intern Med J 2003; 33:33-43.
9. Storm FK, Sparks FC, Morton DL. Treatment for melanoma of the lower extremity with intralesional injection of bacille Calmette Guerin and hyperthermic perfusion. Surg Gynecol Obstet 1979; 149:17-21.
10. Waddill W 3rd, Wright W Jr, Unger E, Stopeck A, Akporiaye E, Harris D, et al. Human gene therapy for melanoma: CT-guided interstitial injection. Am J Roentgenol 1997; 169:63-67.
11. Oratz R, Hauschild A, Sebastian G, Schadendorf D, Castro D, Brocker EB, et al. Intratumoral cisplatin/adrenaline injectable gel for the treatment of patients with cutaneous and soft tissue metastases of malignant melanoma. Melanoma Res 2003; 13:59-66.
12. Kubin RH, Grodsky GM, Carbone JV. Investigation of rose bengal conjugation. Proc Soc Exp Biol Med 1960; 104:650-653.
13. Pirotte J. Suitability criteria for compartmental analysis of the plasma clearance curve of exogenous cholephils. 131I rose bengal fulfils these criteria. Biomedicine 1979; 30:211-215.
14. Wachter E, Dees C, Harkins J, Fisher W, Scott T. Imaging photosensitizer distribution and pharmacology using multiphoton microscopy. Proceedings of SPIE, optical diagnostics of living cells V, Farkas DL, Leif RC, editors. Bellingham, Washington: 2002; 4622:112-118.
15. Mousavi H, Zhang X, Gillespie S, Wachter E, Hersey P. Rose bengal induces dual modes of cell death in melanoma cells and has clinical activity against melanoma. Melanoma Res 2006; 16 (Suppl 1):S8.
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-216.
17. Sersa G, Stabuc B, Cemazar M, Miklavcic D, Rudolf Z. Electrochemotherapy with cisplatin: the systemic antitumour effectiveness of cisplatin can be potentiated locally by the application of electric pulses in the treatment of malignant melanoma skin metastases. Melanoma Res 2000; 10:381-385.
18. Byrne CM, Thompson JF, Johnston H, Hersey P, Quinn MJ, Michael Hughes T, McCarthy WH. Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Res 2005; 15:45-51.
19. Gaudy C, Richard MA, Folchetti G, Bonerandi JJ, Grob JJ. Randomized controlled study of electrochemotherapy in the local treatment of skin metastases of melanoma. J Cutan Med Surg 2006; 10:115-121.
20. Von Wussow P, Block B, Hartmann F, Deicher H. Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer 1988; 61:1071-1074.
21. Nemunaitis J, Fong T, Robbins JM, Edelman G, Edwards W, Paulson RS, et al. Phase I trial of interferon-gamma (IFN-gamma) retroviral vector administered intratumorally to patients with metastatic melanoma. Cancer Gene Ther 1999; 6:322-330.
22. Khorana AA, Rosenblatt JD, Sahasrabudhe DM, Evans T, Ladrigan M, Marquis D, et al. A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma. Cancer Gene Ther 2003; 10:251-259.
23. Radny P, Caroli UM, Bauer J, Paul T, Schlegel C, Eigentier TK, et al. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer 2003; 89:1620-1626.
24. Green DS, Bodman-Smith MD, Dalgleish AG, Fischer MD. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol 2007; 156:337-345.
25. Stopeck AT, Jones A, Hersh EM, Thompson JA, Finucane DM, Gutheil JC, Gonzalez R. Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma. Clin Cancer Res 2001; 7:2285-2291.
26. Gonzalez R, Hutchins L, Nemunaitis J, Atkins M, Schwarzenberger PO. Phase 2 trial of Allovectin-7 in advanced metastatic melanoma. Melanoma Res 2006; 16:521-526.
27. Tan JK, Ho VC. Pooled analysis of the efficacy of Bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma. J Dermatol Surg Oncol 1993; 19:985-990.